COMPANY

Syndeio Biosciences

HQ: Indianapolis, IN source · syndeio.bio ↗

Keywords: psychiatry Major Depressive Disorder Excessive Sleepiness Zelquistinel AGN-241751 GATE-101

Location: Indianapolis, IN · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Jan 5, 2026 Trial start 2: A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder source ↗
Jul 24, 2025 Trial start Phase 1: Pharmacokinetics of Zelquistinel in Fasted or Fed State source ↗
Feb 3, 2025 Trial start Phase 2: Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder source ↗
Oct 15, 2022 Trial start Phase 1: Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers source ↗
Oct 26, 2020 Trial start Phase 1: Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers source ↗
Nov 8, 2018 Trial start Phase 1/Phase 2: Zelquistinel in the Treatment of Adults With Major Depressive Disorder source ↗
Jun 13, 2018 Trial start Phase 2: Zelquistinel in the Treatment of Major Depressive Disorder source ↗
Dec 9, 2016 Trial start Phase 1: Safety and Tolerability of Zelquistinel in Normal Human Volunteers source ↗

2027-09 (ESTIMATED) · Phase 2 · Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder · NCT06547489
Mar 30, 2028 (ESTIMATED) · 2 · A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder · NCT07115329

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06547489	Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder	Phase 2	Recruiting	Feb 3, 2025	2027-09 (estimated)
NCT07115329	A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder	2	Recruiting	Jan 5, 2026	Mar 30, 2028 (estimated)
NCT03586427	Zelquistinel in the Treatment of Major Depressive Disorder	Phase 2	Completed	Jun 13, 2018	Jul 22, 2019 (actual)
NCT03726658	Zelquistinel in the Treatment of Adults With Major Depressive Disorder	Phase 1/Phase 2	Completed	Nov 8, 2018	Oct 23, 2019 (actual)
NCT07099989	Pharmacokinetics of Zelquistinel in Fasted or Fed State	Phase 1	Active, not recruiting	Jul 24, 2025	Feb 5, 2026 (actual)
NCT04981561	Safety and Tolerability of Zelquistinel in Normal Human Volunteers	Phase 1	Completed	Dec 9, 2016	Dec 21, 2017 (actual)
NCT05597241	Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers	Phase 1	Completed	Oct 15, 2022	Apr 4, 2023 (actual)
NCT04618263	Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers	Phase 1	Terminated	Oct 26, 2020	Aug 13, 2021 (actual)